Helen M. Thackray, VP Clinical Development, CMO at GLYCOMIMETICS INC (GLYC), sold 4,000 shares at $7.00 ($28K) on 2016-10-03, disclosed to the SEC on 2016-10-04.
Scheduled sale ($28k) by VP Clinical Development, CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.00 | 3,900 | $27K | 97.5% |
| 2 | $7.01 | 100 | $701 | 2.5% |
| Total | $7.00 avg | 4,000 | $28K | 100% |
| Filing → |
| BCRX | SELL | 2022-12-19 | $34K | — | Filing → |
| BCRX | SELL | 2022-04-04 | $123K | — | Filing → |
| GLYC | SELL | 2017-12-12 | $30K | — | Filing → |